Overview
Cediranib is a small-molecule tyrosine kinase inhibitor developed by AstraZeneca, primarily targeting vascular endothelial growth factor receptors (VEGFR-1, -2, and -3). It disrupts tumor angiogenesis by blocking VEGF signaling pathways, thereby starving tumors of blood supply. As a research compound, it has shown promise in Phase II/III trials for various cancers, often combined with other therapies like olaparib. Initially code-named AZD2171, cediranib received the trade name Recentin but is not widely marketed commercially. Its primary use remains in academic and pharmaceutical research settings, particularly for investigating anti-angiogenesis strategies in oncology.
Physical and Chemical Properties
Cediranib presents as a white crystalline powder with moderate stability under controlled conditions. Its molecular structure includes a quinazoline core, contributing to its high affinity for VEGFRs. The compound demonstrates pH-dependent solubility, with optimal dissolution in dimethyl sulfoxide (DMSO). Thermogravimetric analysis shows decomposition above 205°C. It exhibits fluorescence under UV light (λex 260nm), a property utilized in analytical quantification. Researchers should note its photosensitivity; solutions degrade under prolonged light exposure, necessitating amber glassware for storage.
Main Applications
In clinical research, cediranib has been evaluated for recurrent ovarian cancer (combined with PARP inhibitors), metastatic colorectal cancer, and glioblastoma multiforme. Its anti-angiogenic mechanism complements cytotoxic therapies by normalizing tumor vasculature, improving drug delivery. Preclinical studies utilize cediranib in xenograft models to investigate metastasis inhibition. At nanomolar concentrations (IC50 ~1nM for VEGFR-2), it effectively blocks endothelial cell proliferation. Recent exploratory applications include retinal diseases and pulmonary hypertension, leveraging its VEGF pathway modulation.
Safety and Storage
As a bioactive pharmaceutical intermediate, cediranib requires handling in fume hoods with nitrile gloves and lab coats. Powder forms may become airborne; use respiratory protection during weighing. Spills should be contained with inert absorbents and disposed as hazardous waste. Long-term storage demands desiccated environments (-20°C) under argon to prevent oxidation. Solutions in DMSO are stable for 3 months when aliquoted and frozen. Avoid freeze-thaw cycles beyond three repetitions to maintain potency. Material Safety Data Sheets (MSDS) must be consulted prior to use.
B2B Procurement Guide
Bulk procurement (>100g) typically requires 8-12 weeks lead time due to synthesis complexity. Reputable suppliers provide batch-specific COAs with HPLC purity (>98%), residual solvent analysis, and mass spectrometry verification. Key red flags include missing NMR spectra or inconsistent melting point data. For international shipments, ensure suppliers can prepare CITES documentation and FDA Drug Master Files if applicable. Consider cold chain logistics for tropical climates. Spot prices fluctuate based on clinical trial demand; contract manufacturing arrangements often yield 15-20% cost reductions for multi-kilogram orders.